The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Cited by (1,105)

Items 1,001–1,100 of 1,105

1. Network Propagation Predicts Drug Synergy in Cancers
   Hongyang Li, Tingyang Li, Daniel X. Quang, Yuanfang Guan · 2018 · Cancer Research
2. Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c‐Jun pathway in adaptive resistance to drug‐induced apoptosis
   Fallahi‐Sichani, Mohammad, Moerke, Nathan J, Niepel, Mario, Zhang, Tinghu, Gray, Nathanael S, Sorger, Peter K · 2015 · Molecular Systems Biology
3. A Six‐Stage Workflow for Robust Application of Systems Pharmacology
   Gadkar, K, Kirouac, DC, Mager, DE, van der Graaf, PH, Ramanujan, S · 2016 · CPT: Pharmacometrics & Systems Pharmacology
4. Differentiable biology: using deep learning for biophysics-based and data-driven modeling of molecular mechanisms
   AlQuraishi, Mohammed, Sorger, Peter K. · 2021 · Nature Methods
5. Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
   Momcilovic, M, Shackelford, D B · 2015 · British Journal of Cancer
6. Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics
   de Waal, Luc, Lewis, Timothy A, Rees, Matthew G, Tsherniak, Aviad, Wu, Xiaoyun, Choi, Peter S, Gechijian, Lara, Hartigan, Christina, Faloon, Patrick W, Hickey, Mark J et al. · 2016 · Nature Chemical Biology
7. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
   Lu, Hengyu, Liu, Chen, Velazquez, Roberto, Wang, Hongyun, Dunkl, Lukas Manuel, Kazic-Legueux, Malika, Haberkorn, Anne, Billy, Eric, Manchado, Eusebio, Brachmann, Saskia M. et al. · 2019 · Molecular Cancer Therapeutics
8. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
   Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E. et al. · 2018 · Clinical Cancer Research
9. Molecular basis for substrate recruitment to the PRMT5 methylosome
   Mulvaney, Kathleen M., Blomquist, Christa, Acharya, Nischal, Li, Ruitong, Ranaghan, Matthew J., O’Keefe, Meghan, Rodriguez, Diego J., Young, Michael J., Kesar, Devishi, Pal, Debjani et al. · 2021 · Molecular Cell
10. LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT
    Kaufman, Jacob M., Amann, Joseph M., Park, Kyungho, Arasada, Rajeswara Rao, Li, Haotian, Shyr, Yu, Carbone, David P. · 2014 · Journal of Thoracic Oncology
11. An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development
    van Pel, Derek M., Barrett, Irene J., Shimizu, Yoko, Sajesh, Babu V., Guppy, Brent J., Pfeifer, Tom, McManus, Kirk J., Hieter, Philip · 2013 · PLoS Genetics
12. A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
    Jeay, Sébastien, Gaulis, Swann, Ferretti, Stéphane, Bitter, Hans, Ito, Moriko, Valat, Thérèse, Murakami, Masato, Ruetz, Stephan, Guthy, Daniel A, Rynn, Caroline et al. · 2015 · eLife
13. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates
    Nguyen, Thang Van, Li, Jing, Lu, Chin-Chun (Jean), Mamrosh, Jennifer L., Lu, Gang, Cathers, Brian E., Deshaies, Raymond J. · 2017 · Proceedings of the National Academy of Sciences
14. Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
    Jeay, Sébastien, Ferretti, Stéphane, Holzer, Philipp, Fuchs, Jeanette, Chapeau, Emilie A., Wartmann, Markus, Sterker, Dario, Romanet, Vincent, Murakami, Masato, Kerr, Grainne et al. · 2018 · Cancer Research
15. The potential of organoids in urological cancer research
    Wang, Shangqian, Gao, Dong, Chen, Yu · 2017 · Nature Reviews Urology
16. Linking Phenotypes and Modes of Action Through High-Content Screen Fingerprints
    Reisen, Felix, Sauty de Chalon, Amelie, Pfeifer, Martin, Zhang, Xian, Gabriel, Daniela, Selzer, Paul · 2015 · ASSAY and Drug Development Technologies
17. Identifying robust communities and multi-community nodes by combining top-down and bottom-up approaches to clustering
    Gaiteri, Chris, Chen, Mingming, Szymanski, Boleslaw, Kuzmin, Konstantin, Xie, Jierui, Lee, Changkyu, Blanche, Timothy, Chaibub Neto, Elias, Huang, Su-Chun, Grabowski, Thomas et al. · 2015 · Scientific Reports
18. A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines
    Bian, Xiaocui, Yang, Zhenli, Feng, Hailiang, Sun, Hao, Liu, Yuqin · 2017 · Scientific Reports
19. Determinants of transcription factor regulatory range
    Chen, Chen-Hao, Zheng, Rongbin, Tokheim, Collin, Dong, Xin, Fan, Jingyu, Wan, Changxin, Tang, Qin, Brown, Myles, Liu, Jun S., Meyer, Clifford A. et al. · 2020 · Nature Communications
20. Predicting and characterizing a cancer dependency map of tumors with deep learning
    Chiu, Yu-Chiao, Zheng, Siyuan, Wang, Li-Ju, Iskra, Brian S., Rao, Manjeet K., Houghton, Peter J., Huang, Yufei, Chen, Yidong · 2021 · Science Advances
21. Interpretation of cancer mutations using a multiscale map of protein systems
    Zheng, Fan, Kelly, Marcus R., Ramms, Dana J., Heintschel, Marissa L., Tao, Kai, Tutuncuoglu, Beril, Lee, John J., Ono, Keiichiro, Foussard, Helene, Chen, Michael et al. · 2021 · Science
22. RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
    Depeille, Philippe, Henricks, Linda M., van de Ven, Robert A. H., Lemmens, Ed, Wang, Chih-Yang, Matli, Mary, Werb, Zena, Haigis, Kevin M., Donner, David, Warren, Robert et al. · 2015 · Nature Cell Biology
23. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies
    Li, Yan, Xu, Chen, Wang, Bing, Xu, Fujiang, Ma, Fahan, Qu, Yuanyuan, Jiang, Dongxian, Li, Kai, Feng, Jinwen, Tian, Sha et al. · 2022 · Nature Communications
24. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
    Bower, Jacquelyn J., Vance, Leah D., Psioda, Matthew, Smith-Roe, Stephanie L., Simpson, Dennis A., Ibrahim, Joseph G., Hoadley, Katherine A., Perou, Charles M., Kaufmann, William K. · 2017 · npj Breast Cancer
25. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
    Wang, Ye, Mohseni, Morvarid, Grauel, Angelo, Diez, Javier Estrada, Guan, Wei, Liang, Simon, Choi, Jiyoung Elizabeth, Pu, Minying, Chen, Dongshu, Laszewski, Tyler et al. · 2021 · Scientific Reports
26. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
    Kloth, Michael, Ruesseler, Vanessa, Engel, Christoph, Koenig, Katharina, Peifer, Martin, Mariotti, Erika, Kuenstlinger, Helen, Florin, Alexandra, Rommerscheidt-Fuss, Ursula, Koitzsch, Ulrike et al. · 2016 · Gut
27. Paralog dependency indirectly affects the robustness of human cells
    Dandage, Rohan, Landry, Christian R · 2019 · Molecular Systems Biology
28. Cell Membrane Proteins Modulate the Carbon Nanotube Optical Bandgap <i>via</i> Surface Charge Accumulation
    Roxbury, Daniel, Jena, Prakrit V., Shamay, Yosi, Horoszko, Christopher P., Heller, Daniel A. · 2016 · ACS Nano
29. Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
    Marisa, Laetitia, Blum, Yuna, Taieb, Julien, Ayadi, Mira, Pilati, Camilla, Le Malicot, Karine, Lepage, Côme, Salazar, Ramon, Aust, Daniela, Duval, Alex et al. · 2021 · Clinical Cancer Research
30. Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity
    Deng, Lei, Cai, Yideng, Zhang, Wenhao, Yang, Wenyi, Gao, Bo, Liu, Hui · 2020 · Journal of Chemical Information and Modeling
31. Glycine decarboxylase maintains mitochondrial protein lipoylation to support tumor growth
    Mukha, Dzmitry, Fokra, Mariam, Feldman, Alona, Sarvin, Boris, Sarvin, Nikita, Nevo-Dinur, Keren, Besser, Elazar, Hallo, Elior, Aizenshtein, Elina, Schug, Zachary T. et al. · 2022 · Cell Metabolism
32. Multilevel models Improve precision and Speed of IC ₅₀ Estimates
    Vis, Daniel J, Bombardelli, Lorenzo, Lightfoot, Howard, Iorio, Francesco, Garnett, Mathew J, Wessels, Lodewyk FA · 2016 · Pharmacogenomics
33. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
    Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun · 2018 · Cell Death &amp; Disease
34. Predicting heterogeneity in clone-specific therapeutic vulnerabilities using single-cell transcriptomic signatures
    Suphavilai, Chayaporn, Chia, Shumei, Sharma, Ankur, Tu, Lorna, Da Silva, Rafael Peres, Mongia, Aanchal, DasGupta, Ramanuj, Nagarajan, Niranjan · 2021 · Genome Medicine
35. A systematic study on drug-response associated genes using baseline gene expressions of the cancer cell line encyclopedia
    Liu, Xiaoming, Yang, Jiasheng, Zhang, Yi, Fang, Yun, Wang, Fayou, Wang, Jun, Zheng, Xiaoqi, Yang, Jialiang · 2016 · Scientific Reports
36. A community challenge for a pancancer drug mechanism of action inference from perturbational profile data
    Douglass, Eugene F., Allaway, Robert J., Szalai, Bence, Wang, Wenyu, Tian, Tingzhong, Fernández-Torras, Adrià, Realubit, Ron, Karan, Charles, Zheng, Shuyu, Pessia, Alberto et al. · 2022 · Cell Reports Medicine
37. Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs
    Saqcena, M, Mukhopadhyay, S, Hosny, C, Alhamed, A, Chatterjee, A, Foster, D A · 2015 · Oncogene
38. USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia
    Shan, Huizhuang, Li, Xiangyun, Xiao, Xinhua, Dai, Yuting, Huang, Jinyan, Song, Junjun, Liu, Meng, Yang, Li, Lei, Hu, Tong, Yin et al. · 2018 · Signal Transduction and Targeted Therapy
39. COX6B2 drives metabolic reprogramming toward oxidative phosphorylation to promote metastasis in pancreatic ductal cancer cells
    Nie, Ke, Li, Jin, He, Xujun, Wang, Yuqing, Zhao, Qiongya, Du, Miaomiao, Sun, Hongwei, Wang, Jinjing, Lyu, Jianxin, Fang, Hezhi et al. · 2020 · Oncogenesis
40. An in vivo multiplexed small-molecule screening platform
    Grüner, Barbara M, Schulze, Christopher J, Yang, Dian, Ogasawara, Daisuke, Dix, Melissa M, Rogers, Zoë N, Chuang, Chen-Hua, McFarland, Christopher D, Chiou, Shin-Heng, Brown, J Mark et al. · 2016 · Nature Methods
41. Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
    Zeng, Hao, Castillo-Cabrera, Johnny, Manser, Mika, Lu, Bo, Yang, Zinger, Strande, Vaik, Begue, Damien, Zamponi, Raffaella, Qiu, Shumei, Sigoillot, Frederic et al. · 2019 · eLife
42. Integrating and formatting biomedical data as pre-calculated knowledge graph embeddings in the Bioteque
    Fernández-Torras, Adrià, Duran-Frigola, Miquel, Bertoni, Martino, Locatelli, Martina, Aloy, Patrick · 2022 · Nature Communications
43. A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens
    Bouhaddou, Mehdi, Barrette, Anne Marie, Stern, Alan D., Koch, Rick J., DiStefano, Matthew S., Riesel, Eric A., Santos, Luis C., Tan, Annie L., Mertz, Alex E., Birtwistle, Marc R. · 2018 · PLOS Computational Biology
44. HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
    Yang, Haitang, Liang, Shun-Qing, Xu, Duo, Yang, Zhang, Marti, Thomas M., Gao, Yanyun, Kocher, Gregor J., Zhao, Heng, Schmid, Ralph A., Peng, Ren-Wang · 2019 · Oncogenesis
45. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors
    Kaipio, Katja, Chen, Ping, Roering, Pia, Huhtinen, Kaisa, Mikkonen, Piia, Östling, Päivi, Lehtinen, Laura, Mansuri, Naziha, Korpela, Taina, Potdar, Swapnil et al. · 2020 · The Journal of Pathology
46. The lncRNA Toolkit: Databases and In Silico Tools for lncRNA Analysis
    Pinkney, Holly R., Wright, Brandon M., Diermeier, Sarah D. · 2020 · Non-Coding RNA
47. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
    Hao, Huai-Xiang, Wang, Hongyun, Liu, Chen, Kovats, Steven, Velazquez, Roberto, Lu, Hengyu, Pant, Bhavesh, Shirley, Matthew, Meyer, Matthew J., Pu, Minying et al. · 2019 · Molecular Cancer Therapeutics
48. Towards artificial intelligence to multi-omics characterization of tumor heterogeneity in esophageal cancer
    Li, Junyu, Li, Lin, You, Peimeng, Wei, Yiping, Xu, Bin · 2023 · Seminars in Cancer Biology
49. OCTAD: an open workspace for virtually screening therapeutics targeting precise cancer patient groups using gene expression features
    Zeng, Billy, Glicksberg, Benjamin S., Newbury, Patrick, Chekalin, Evgeny, Xing, Jing, Liu, Ke, Wen, Anita, Chow, Caven, Chen, Bin · 2021 · Nature Protocols
50. The Flint Animal Cancer Center (<scp>FACC</scp>) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine
    Fowles, J. S., Dailey, D. D., Gustafson, D. L., Thamm, D. H., Duval, D. L. · 2017 · Veterinary and Comparative Oncology
51. Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
    Mundi, Prabhjot S., Dela Cruz, Filemon S., Grunn, Adina, Diolaiti, Daniel, Mauguen, Audrey, Rainey, Allison R., Guillan, Kristina C., Siddiquee, Armaan, You, Daoqi, Realubit, Ronald et al. · 2021
52. Computational identification of multi-omic correlates of anticancer therapeutic response
    Stetson, Lindsay C, Pearl, Taylor, Chen, Yanwen, Barnholtz-Sloan, Jill S · 2014 · BMC Genomics
53. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
    Stover, Elizabeth H., Baco, Maria B., Cohen, Ofir, Li, Yvonne Y., Christie, Elizabeth L., Bagul, Mukta, Goodale, Amy, Lee, Yenarae, Pantel, Sasha, Rees, Matthew G. et al. · 2019 · Molecular Cancer Research
54. Metabolic impairment of non-small cell lung cancers by mitochondrial HSPD1 targeting
    Parma, Beatrice, Ramesh, Vignesh, Gollavilli, Paradesi Naidu, Siddiqui, Aarif, Pinna, Luisa, Schwab, Annemarie, Marschall, Sabine, Zhang, Shuman, Pilarsky, Christian, Napoli, Francesca et al. · 2021 · Journal of Experimental &amp; Clinical Cancer Research
55. Comprehensive pharmacogenomic characterization of gastric cancer
    Sa, Jason K., Hong, Jung Yong, Lee, In-Kyoung, Kim, Ju-sun, Sim, Moon-Hee, Kim, Ha Jung, An, Ji Yeong, Sohn, Tae Sung, Lee, Joon Ho, Bae, Jae Moon et al. · 2020 · Genome Medicine
56. Artificial intelligence in radiotherapy
    Li, Guangqi, Wu, Xin, Ma, Xuelei · 2022 · Seminars in Cancer Biology
57. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
    Shee, Kevin, Wells, Jason D., Jiang, Amanda, Miller, Todd W. · 2019 · PLOS ONE
58. Network control principles for identifying personalized driver genes in cancer
    Guo, Wei-Feng, Zhang, Shao-Wu, Zeng, Tao, Akutsu, Tatsuya, Chen, Luonan · 2020 · Briefings in Bioinformatics
59. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
    Smida, Michal, Fece de la Cruz, Ferran, Kerzendorfer, Claudia, Uras, Iris Z., Mair, Barbara, Mazouzi, Abdelghani, Suchankova, Tereza, Konopka, Tomasz, Katz, Amanda M., Paz, Keren et al. · 2016 · Nature Communications
60. Efforts to Develop KRAS Inhibitors
    Holderfield, Matthew · 2018 · Cold Spring Harbor Perspectives in Medicine
61. Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
    Patyka, Mariia, Sharifi, Zeinab, Petrecca, Kevin, Mansure, Jose, Jean-Claude, Bertrand, Sabri, Siham · 2016 · Oncotarget
62. Identification and Characterization of Oncogenic <i>SOS1</i> Mutations in Lung Adenocarcinoma
    Cai, Diana, Choi, Peter S., Gelbard, Maya, Meyerson, Matthew · 2019 · Molecular Cancer Research
63. False and mycoplasma-contaminated leukemia-lymphoma cell lines: time for a reappraisal
    Drexler, Hans G., Dirks, Wilhelm G., MacLeod, Roderick A.F., Uphoff, Cord C. · 2017 · International Journal of Cancer
64. Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours
    Naulaerts, Stefan, Dang, Cuong C., Ballester, Pedro J. · 2017 · Oncotarget
65. Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
    Schadt, Eric E., Buchanan, Sean, Brennand, Kristen J., Merchant, Kalpana M. · 2014 · Frontiers in Pharmacology
66. Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of <i>ATG5</i>
    García-Fernández, María, Karras, Panagiotis, Checinska, Agnieszka, Cañón, Estela, Calvo, Guadalupe T., Gómez-López, Gonzalo, Cifdaloz, Metehan, Colmenar, Angel, Espinosa-Hevia, Luis, Olmeda, David et al. · 2016 · Autophagy
67. Dasatinib sensitises KRAS -mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
    Rao, Guanhua, Kim, In-kyu, Conforti, Fabio, Liu, Jing, Zhang, Yu-Wen, Giaccone, Giuseppe · 2018 · European Journal of Cancer
68. Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
    Saunus, Jodi M., Smart, Chanel E., Kutasovic, Jamie R., Johnston, Rebecca L., Kalita-de Croft, Priyakshi, Miranda, Mariska, Rozali, Esdy N., Vargas, Ana Cristina, Reid, Lynne E., Lorsy, Eva et al. · 2018 · Breast Cancer Research and Treatment
69. The opportunities of mining historical and collective data in drug discovery
    Wassermann, Anne Mai, Lounkine, Eugen, Davies, John W., Glick, Meir, Camargo, L. Miguel · 2015 · Drug Discovery Today
70. Deep learning prediction of chemical-induced dose-dependent and context-specific multiplex phenotype responses and its application to personalized alzheimer’s disease drug repurposing
    Wu, You, Liu, Qiao, Qiu, Yue, Xie, Lei · 2022 · PLOS Computational Biology
71. MATE2 Expression Is Associated With Cancer Cell Response to Metformin
    Chowdhury, Sanjana, Yung, Eric, Pintilie, Melania, Muaddi, Hala, Chaib, Selim, Yeung, ManTek, Fusciello, Manlio, Sykes, Jenna, Pitcher, Bethany, Hagenkort, Anna et al. · 2016 · PLoS ONE
72. High-throughput 3-dimensional Culture of Epithelial Ovarian Cancer Cells as Preclinical Model of Disease
    Heredia-Soto, Victoria, Redondo, Andrés, Berjón, Alberto, Miguel-Martín, María, Díaz, Esther, Crespo, Roberto, Hernández, Alicia, Yébenes, Laura, Gallego, Alejandro, Feliu, Jaime et al. · 2018 · Oncotarget
73. Computational estimation of quality and clinical relevance of cancer cell lines
    Trastulla, Lucia, Noorbakhsh, Javad, Vazquez, Francisca, McFarland, James, Iorio, Francesco · 2022 · Molecular Systems Biology
74. EZH2 promotes DNA replication by stabilizing interaction of POLδ and PCNA via methylation-mediated PCNA trimerization
    A, Peng, Xu, Xinyi, Wang, Chenglin, Yang, Jing, Wang, Shida, Dai, Jiewen, Ye, Ling · 2018 · Epigenetics &amp; Chromatin
75. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer
    Prahallad, Anirudh, Weiss, Andreas, Voshol, Hans, Kerr, Grainne, Sprouffske, Kathleen, Yuan, Tina, Ruddy, David, Meistertzheim, Morgane, Kazic-Legueux, Malika, Kottarathil, Tina et al. · 2023 · Cancer Research
76. Models of renal cell carcinoma used to investigate molecular mechanisms and develop new therapeutics
    Shapiro, Daniel D., Virumbrales-Muñoz, Maria, Beebe, David J., Abel, E. Jason · 2022 · Frontiers in Oncology
77. The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
    Paris, Anaïs, Tardif, Nina, Baietti, Francesca M, Berra, Cyrille, Leclair, Héloïse M, Leucci, Eleonora, Galibert, Marie‐Dominique, Corre, Sébastien · 2022 · EMBO Molecular Medicine
78. Formatting biological big data for modern machine learning in drug discovery
    Duran‐Frigola, Miquel, Fernández‐Torras, Adrià, Bertoni, Martino, Aloy, Patrick · 2019 · WIREs Computational Molecular Science
79. ELP-dependent expression of <i>MCL1</i> promotes resistance to EGFR inhibition in triple-negative breast cancer cells
    Cruz-Gordillo, Peter, Honeywell, Megan E., Harper, Nicholas W., Leete, Thomas, Lee, Michael J. · 2020 · Science Signaling
80. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity
    Wu, D, Pang, Y, Wilkerson, M D, Wang, D, Hammerman, P S, Liu, J S · 2013 · British Journal of Cancer
81. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
    Pietarinen, P O, Pemovska, T, Kontro, M, Yadav, B, Mpindi, J P, Andersson, E I, Majumder, M M, Kuusanmäki, H, Koskenvesa, P, Kallioniemi, O et al. · 2015 · Blood Cancer Journal
82. Transmembrane and Immunoglobulin Domain Containing 1, a Putative Tumor Suppressor, Induces G2/M Cell Cycle Checkpoint Arrest in Colon Cancer Cells
    De La Cena, Kyle O.C., Ho, Rachel X.-Y., Amraei, Razie, Woolf, Nick, Tashjian, Joseph Y., Zhao, Qing, Richards, Sean, Walker, Josh, Huang, Juanni, Chitalia, Vipul C. et al. · 2021 · The American Journal of Pathology
83. Association of transcriptional levels of folate-mediated one-carbon metabolism-related genes in cancer cell lines with drug treatment response
    Min, Dong-Joon, Vural, Suleyman, Krushkal, Julia · 2019 · Cancer Genetics
84. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
    Funingana, Ionut-Gabriel, Reinius, Marika A.V., Petrillo, Angelica, Ang, Joo Ern, Brenton, James D. · 2021 · Seminars in Cancer Biology
85. A proteomic platform to identify off-target proteins associated with therapeutic modalities that induce protein degradation or gene silencing
    Liu, Xin, Zhang, Ye, Ward, Lucas D., Yan, Qinghong, Bohnuud, Tanggis, Hernandez, Rocio, Lao, Socheata, Yuan, Jing, Fan, Fan · 2021 · Scientific Reports
86. Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers
    Wu, Su, Wagner, Gerhard · 2021 · Cell Systems
87. Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?
    Vazquez, Francisca, Sellers, William R. · 2021 · Cancer Research
88. CeL-ID: cell line identification using RNA-seq data
    Mohammad, Tabrez A., Tsai, Yun S., Ameer, Safwa, Chen, Hung-I Harry, Chiu, Yu-Chiao, Chen, Yidong · 2019 · BMC Genomics
89. Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells
    Ceder, Sophia, Eriksson, Sofi E., Liang, Ying Yu, Cheteh, Emarndeena H., Zhang, Si Min, Fujihara, Kenji M., Bianchi, Julie, Bykov, Vladimir J. N., Abrahmsen, Lars, Clemons, Nicholas J. et al. · 2021 · Cell Death &amp; Disease
90. Cell banking for pharmaceutical research
    Wrigley, Jonathan D., McCall, Eileen J., Bannaghan, Claire L., Liggins, Laura, Kendrick, Clare, Griffen, Alison, Hicks, Ryan, Fröderberg-Roth, Linda · 2014 · Drug Discovery Today
91. KCML: a machine-learning framework for inference of multi-scale gene functions from genetic perturbation screens
    Sailem, Heba Z, Rittscher, Jens, Pelkmans, Lucas · 2020 · Molecular Systems Biology
92. A proof of concept for targeting the PrPC - Amyloid β peptide interaction in basal prostate cancer and mesenchymal colon cancer
    Mouillet-Richard, Sophie, Martin-Lannerée, Séverine, Le Corre, Delphine, Hirsch, Théo Z., Ghazi, Alexandre, Sroussi, Marine, Pilati, Camilla, de Reyniès, Aurélien, Djouadi, Fatima, Vodovar, Nicolas et al. · 2022 · Oncogene
93. A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
    Foote, Jeremy B., Mattox, Tyler E., Keeton, Adam B., Chen, Xi, Smith, Forrest, Berry, Kristy L., Holmes, Thomas, Wang, Junwei, Huang, Chung-Hui, Ward, Antonio B. et al. · 2023
94. Phosphorylation-mediated conformational change regulates human SLFN11
    Kugler, Michael, Metzner, Felix J., Witte, Gregor, Hopfner, Karl-Peter, Lammens, Katja · 2024 · Nature Communications
95. The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies
    Babagana, Mahamat, Kichina, Julia V., Slabodkin, Hannah, Johnson, Sydney, Maslov, Alexei, Brown, Lorin, Attwood, Kristopher, Nikiforov, Mikhail A., Kandel, Eugene S. · 2020 · Molecular Carcinogenesis
96. Multidimensional profiling in the investigation of small-molecule-induced cell death
    Wolpaw, Adam J., Stockwell, Brent R. · 2014 · Methods in Enzymology
97. In vitro models of cancer
    Boussommier-Calleja, Alexandra · 2020 · Bioengineering Innovative Solutions for Cancer
98. Downregulation of FTL decreases proliferation of malignant mesothelioma cells by inducing G₁ cell cycle arrest
    Kambara, Takahiro, Amatya, Vishwa, Kushitani, Kei, Fujii, Yutaro, Endo, Ihiro, Takeshima, Yukio · 2022 · Oncology Letters
99. Mesenchymal‐like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial‐like counterparts
    Sinha, Arkadeep, Cherba, David, Bartlam, Heather, Lenkiewicz, Elizabeth, Evers, Lisa, Barrett, Michael T., Haab, Brian B. · 2014 · Molecular Oncology
100. Detecting fabrication in large-scale molecular omics data
     Bradshaw, Michael S., Payne, Samuel H. · 2021 · PLOS ONE